GO:1905048 regulation of metallopeptidase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905048 (regulation of metallopeptidase activity) is a biological process that modulates the frequency, rate, or extent of metallopeptidase activity, a class of enzymes that cleave peptide bonds using a metal ion cofactor.
• Metallopeptidase activity is regulated at multiple levels, including reversible autoinhibition, C-terminal domain interactions, and proteolytic processing, as shown for BepA, insulin-regulated aminopeptidase, and PARL.
• Dysregulation of metallopeptidases such as matrix metalloproteinases (MMPs) and PAPP-A contributes to cancer progression, skeletal malignancy, and cardiovascular pathology.
• Key regulatory proteins include PARL, BepA, ulilysin, PAPP-A, and IRAP, which serve as models for understanding latency, activation, and substrate selectivity.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models are essential to dissect the causal roles of metallopeptidase regulators in disease.
• EDITGENE provides end-to-end services for generating and screening these models, enabling high-throughput functional genomics of metallopeptidase regulation.
Description
Metallopeptidases are a large family of proteolytic enzymes that require a divalent metal ion, typically zinc, for catalysis. They participate in diverse biological processes, from protein quality control to cell signaling and tissue remodeling. The Gene Ontology term GO:1905048, regulation of metallopeptidase activity, describes any process that modulates the frequency, rate, or extent of metallopeptidase activity. This regulatory layer is critical because uncontrolled proteolysis can lead to pathological outcomes such as cancer invasion, neurodegeneration, and metabolic disorders. Understanding how metallopeptidase activity is controlled at the molecular level is therefore a central question in cell biology and drug discovery. Recent studies have revealed diverse regulatory mechanisms, including autoinhibition, allosteric modulation, and proteolytic processing. For example, the Escherichia coli metallopeptidase BepA undergoes reversible autoinhibitory regulation to selectively degrade β-barrel proteins, while the mitochondrial protease PARL is regulated by its own cleavage and structural rearrangements. These findings highlight the importance of precise regulatory control in maintaining cellular homeostasis. In this article, we synthesize authoritative QuickGO data and verified PubMed literature to provide a comprehensive overview of GO:1905048, covering its definition, mechanisms, key genes, disease relevance, and experimental approaches for researchers.
regulation of metallopeptidase activity At A Glance
| GO ID | GO:1905048 |
|---|---|
| GO term | regulation of metallopeptidase activity |
| Ontology | biological_process |
| Synonym | regulation of metalloprotease activity; regulation of metalloproteinase activity |
| Major function | Modulates the frequency, rate or extent of metallopeptidase activity |
| Related molecular function | metallopeptidase activity (GO:0008237) |
| Related biological process | proteolysis (GO:0006508) |
| Regulation type | Positive and negative regulation |
| Example regulators | PARL, BepA, ulilysin, PAPP-A, IRAP |
What Is GO:1905048?
According to the Gene Ontology, GO:1905048 (regulation of metallopeptidase activity) is defined as any process that modulates the frequency, rate or extent of metallopeptidase activity. This encompasses both positive and negative regulation, including changes in enzyme abundance, catalytic efficiency, or substrate accessibility. Metallopeptidases are proteases that use a metal ion, often zinc, to hydrolyze peptide bonds. Regulation can occur through direct interaction with inhibitors or activators, post-translational modifications, or changes in subcellular localization. The term is synonymous with regulation of metalloprotease activity and regulation of metalloproteinase activity.
Why Is regulation of metallopeptidase activity Important in Cell Biology?
Regulation of metallopeptidase activity is essential for normal physiology and its dysregulation is implicated in numerous diseases. Metallopeptidases such as matrix metalloproteinases (MMPs) are tightly controlled to prevent excessive extracellular matrix degradation, which can promote tumor invasion and metastasis. The pregnancy-associated plasma protein-A (PAPP-A) is a metallopeptidase that regulates insulin-like growth factor bioavailability and has been linked to cancer and cardiovascular disease. In skeletal malignancy, proteolytic regulation of parathyroid hormone-related protein (PTHrP) by metallopeptidases influences tumor growth and bone destruction. Mitochondrial metallopeptidases like PARL regulate apoptosis and calcium homeostasis, and their dysfunction contributes to neurodegeneration. Thus, understanding the regulatory mechanisms of metallopeptidases offers therapeutic opportunities across oncology, metabolic disorders, and neurodegenerative diseases.
• Controls proteolytic cascades in cancer invasion and metastasis.
• Regulates growth factor bioavailability via PAPP-A and IGF signaling.
• Modulates bone remodeling and skeletal malignancy through PTHrP processing.
• Maintains mitochondrial function and apoptosis via PARL.
• Influences protein quality control in bacteria and eukaryotes.
• Affects insulin-regulated aminopeptidase activity and glucose homeostasis.
• Provides targets for drug discovery, e.g., sulfonyl-fluoride inhibitors of ulilysin.
• Dysregulation linked to cardiovascular disease and pregnancy complications.
• Key to understanding latency and activation of secreted metallopeptidases.
• Enables selective degradation of β-barrel proteins in Gram-negative bacteria.
What Happens During regulation of metallopeptidase activity?
Reversible Autoinhibition and Activation
In simple terms: Some metallopeptidases have a built-in safety switch that keeps them inactive until needed.
Many metallopeptidases are synthesized as latent enzymes that require activation. For example, the Escherichia coli metallopeptidase BepA undergoes reversible autoinhibitory regulation, where its own N-terminal domain blocks the active site until a substrate or signal triggers a conformational change. Similarly, the metallopeptidase ulilysin exhibits latency that can be relieved by structural rearrangements, and its activity is unexpectedly inhibited by a sulfonyl-fluoride inhibitor of serine peptidases. This autoinhibition ensures that proteolytic activity is spatially and temporally controlled.
C-Terminal Domain Regulation
In simple terms: The tail end of some enzymes can control how active they are.
The insulin-regulated membrane aminopeptidase (IRAP) is regulated by its C-terminal domain, which modulates its catalytic activity and trafficking. This domain can interact with other proteins or lipids to alter substrate access. Such regulation is critical for insulin-responsive glucose transport and vesicle trafficking.
Proteolytic Processing and Cleavage
In simple terms: Enzymes can cut themselves or each other to turn activity on or off.
The mitochondrial protease PARL is regulated by autocatalytic cleavage, which removes an inhibitory N-terminal peptide and triggers conformational changes that activate the protease. This processing is essential for PARL's role in apoptosis and calcium regulation. Similarly, matrix metalloproteinases (MMPs) are often activated by cleavage of their prodomain by other proteases, a key step in cancer progression.
Transcriptional and Post-Transcriptional Control
In simple terms: Cells can make more or less of the enzyme by controlling gene expression.
Regulation of metallopeptidase activity also occurs at the level of gene expression. MMP genes are transcriptionally induced by growth factors, cytokines, and ECM components, and their mRNAs can be targeted by microRNAs. PAPP-A expression is regulated by hormones and growth factors, influencing IGF bioavailability. This layer of control allows cells to adapt to changing environments.
Inhibitor and Cofactor Interactions
In simple terms: Other molecules can bind to the enzyme and block or enhance its activity.
Tissue inhibitors of metalloproteinases (TIMPs) are endogenous proteins that bind to MMPs and inhibit their activity. Conversely, metal ions such as zinc and calcium are required for catalysis and stability. The activity of ulilysin is dependent on zinc, and its inhibition by sulfonyl-fluoride compounds highlights the potential for small-molecule modulation. These interactions are critical for fine-tuning proteolysis.
Key Genes Involved in GO:1905048 regulation of metallopeptidase activity
The following genes and proteins are key players in the regulation of metallopeptidase activity, as supported by the verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PARL | Mitochondrial metallopeptidase; regulates apoptosis and calcium homeostasis | Neurodegeneration, mitochondrial dynamics |
| BepA | E. coli metallopeptidase; selective β-barrel protein degradation | Bacterial protein quality control |
| IRAP (LNPEP) | Insulin-regulated aminopeptidase; C-terminal domain regulates activity | Glucose homeostasis, vesicle trafficking |
| Ulilysin | Metallopeptidase with latency; inhibited by sulfonyl-fluoride | Enzyme latency and inhibitor design |
| PAPP-A | Metallopeptidase; regulates IGF bioavailability | Cancer, cardiovascular disease, pregnancy |
| MMPs (e.g., MMP2, MMP9) | Matrix metalloproteinases; ECM degradation | Cancer invasion, metastasis |
| PTHrP | Parathyroid hormone-related protein; proteolytically regulated | Skeletal malignancy, bone metastasis |
| TIMP1 | Tissue inhibitor of metalloproteinases | MMP regulation, cancer |
| TIMP2 | Tissue inhibitor of metalloproteinases | MMP regulation, angiogenesis |
| TIMP3 | Tissue inhibitor of metalloproteinases | MMP regulation, inflammation |
| TIMP4 | Tissue inhibitor of metalloproteinases | MMP regulation, cardiac remodeling |
| ACE | Angiotensin-converting enzyme; metallopeptidase | Blood pressure regulation |
| MME (Neprilysin) | Membrane metallopeptidase; degrades amyloid-beta | Alzheimer's disease |
| ECE1 | Endothelin-converting enzyme 1 | Cardiovascular disease |
| ADAM17 | Metallopeptidase; sheds membrane proteins | Inflammation, cancer |
| ADAM10 | Metallopeptidase; Notch signaling | Development, cancer |
| MMP14 (MT1-MMP) | Membrane-type MMP; pericellular proteolysis | Cancer invasion |
How Is regulation of metallopeptidase activity Regulated?
The regulation of metallopeptidase activity is itself subject to multiple layers of control. At the transcriptional level, MMP genes are induced by AP-1, NF-κB, and STAT pathways in response to cytokines and growth factors. Post-transcriptionally, microRNAs and RNA-binding proteins modulate MMP mRNA stability. At the protein level, autoinhibition, proteolytic processing, and interactions with TIMPs provide rapid and reversible control. For example, PARL activity is regulated by its own cleavage and by mitochondrial membrane potential. PAPP-A activity is modulated by its interaction with the IGFBP-4 substrate and by cell surface association. These regulatory mechanisms ensure that metallopeptidase activity is precisely tuned to physiological needs.
regulation of metallopeptidase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MMP9 | Cancer invasion and metastasis | Knockout in cancer cell lines; xenograft models |
| PAPP-A | Cancer, cardiovascular disease | Overexpression and knockout in mice |
| PARL | Neurodegeneration, mitochondrial dysfunction | Point mutation knock-in in neurons |
| PTHrP | Skeletal malignancy | Knock-in of cleavage-resistant mutant in osteosarcoma cells |
| IRAP | Type 2 diabetes | Knockout in adipocytes; glucose uptake assays |
Cancer Progression and Metastasis
Dysregulated metallopeptidase activity is a hallmark of cancer. MMPs, particularly MMP2 and MMP9, degrade extracellular matrix components, facilitating tumor invasion and metastasis. PAPP-A promotes cancer cell proliferation by increasing IGF bioavailability. In skeletal malignancy, proteolytic regulation of PTHrP by metallopeptidases enhances tumor growth and bone destruction. Targeting these regulatory pathways is a promising therapeutic strategy.
Neurodegenerative Disorders
Mitochondrial metallopeptidases such as PARL regulate apoptosis and calcium homeostasis, and their dysfunction is linked to neurodegeneration. Neprilysin (MME) degrades amyloid-beta, and its reduced activity contributes to Alzheimer's disease pathology. Understanding how PARL and other metallopeptidases are regulated may reveal new therapeutic targets.
Cardiovascular and Metabolic Diseases
PAPP-A is implicated in cardiovascular disease and pregnancy complications, where it modulates IGF signaling. IRAP regulates insulin-responsive glucose transport, and its dysregulation is associated with type 2 diabetes. Metallopeptidase inhibitors are being explored for cardiovascular indications.
From regulation of metallopeptidase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PARL affect mitochondrial calcium regulation? | PARL knockout cell lines and point-mutation knock-in |
| How does BepA autoinhibition control substrate selectivity? | BepA point mutations in E. coli |
| What is the role of IRAP C-terminal domain in activity? | IRAP truncation and knock-in mutants |
| Does PAPP-A overexpression promote tumor growth? | PAPP-A overexpression in cancer cell lines and xenografts |
| Can MMP9 knockout reduce metastasis? | MMP9 knockout in mouse models |
| How does ulilysin latency affect inhibitor sensitivity? | Ulilysin point mutations and inhibitor assays |
How to Study the regulation of metallopeptidase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Zymography | Gelatinolytic activity of MMPs | Cancer cell invasion assays |
| FRET peptide assay | Real-time protease kinetics | Inhibitor screening |
| X-ray crystallography | 3D structure of protease-regulator complexes | Mechanistic studies |
| CRISPR knockout screen | Gene essentiality for metallopeptidase activity | Discovery of novel regulators |
| N-terminomics | Proteolytic cleavage sites | Substrate identification |
| Co-immunoprecipitation | Protein-protein interactions | Regulator binding |
| Live-cell imaging | Subcellular localization and activity | PARL dynamics |
| RNA-seq | Transcriptional changes in metallopeptidases | MMP gene expression profiling |
Protease Activity Assays
Enzymatic activity of metallopeptidases can be measured using fluorogenic or colorimetric peptide substrates. For example, MMP activity is often assessed with gelatin zymography or FRET-based peptides. These assays are essential to confirm the impact of regulatory mutations.
Structural Biology
X-ray crystallography and cryo-EM provide mechanistic insights into autoinhibition and activation. The structures of BepA and ulilysin have revealed how regulatory domains block the active site. Such studies guide the design of inhibitors.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify regulators of metallopeptidase activity. For instance, screens for modulators of MMP expression or PAPP-A secretion can uncover novel regulatory pathways. These approaches are high-throughput and unbiased.
Proteomics and Degradomics
Mass spectrometry-based proteomics, including N-terminomics, can identify substrates and cleavage sites of metallopeptidases. This is particularly useful for understanding the downstream effects of regulatory perturbations.
How CRISPR Can Be Used to Study GO:1905048 regulation of metallopeptidase activity
Knockout
CRISPR knockout of metallopeptidase regulators such as PARL or PAPP-A can reveal their essential functions. For example, PARL knockout cells exhibit mitochondrial defects and altered calcium handling. Knockout of MMP9 reduces cancer cell invasion in vitro and metastasis in vivo.
Point Mutation
Point mutations can dissect catalytic and regulatory domains. For instance, mutating the catalytic zinc-binding motif of BepA abolishes its activity, while mutations in the autoinhibitory domain cause constitutive activation. Similarly, point mutations in the C-terminal domain of IRAP alter its activity.
Knock-in
Knock-in of disease-associated or cleavage-resistant mutants provides physiologically relevant models. For example, knock-in of a PTHrP mutant resistant to metallopeptidase cleavage can elucidate its role in skeletal malignancy. Knock-in of tagged PARL allows tracking of its processing in vivo.
Overexpression
Overexpression of metallopeptidases or their regulators can model gain-of-function states. PAPP-A overexpression promotes tumor growth and IGF signaling. Overexpression of MMPs enhances invasion and metastasis in xenograft models.
How EDITGENE Supports regulation of metallopeptidase activity Research
Researchers studying regulation of metallopeptidase activity-related genes often need to determine whether a candidate gene is causally involved in a specific biological process or disease. This requires precise genetic models that can knockout, mutate, knock-in, or overexpress the gene of interest. EDITGENE provides a comprehensive suite of CRISPR services to accelerate such discoveries.
Contact EDITGENE today to design your custom CRISPR model for regulation of metallopeptidase activity research.
Frequently Asked Questions About regulation of metallopeptidase activity
What is GO:1905048?
GO:1905048 is the Gene Ontology term for regulation of metallopeptidase activity, defined as any process that modulates the frequency, rate or extent of metallopeptidase activity.
What genes are involved in regulation of metallopeptidase activity?
Key genes include PARL, BepA, IRAP, ulilysin, PAPP-A, MMPs, and TIMPs, among others.
How is metallopeptidase activity regulated?
It is regulated by autoinhibition, proteolytic processing, C-terminal domain interactions, transcriptional control, and inhibitor binding.
What diseases are associated with dysregulated metallopeptidase activity?
Cancer, neurodegeneration, cardiovascular disease, and metabolic disorders are linked to dysregulated metallopeptidase activity.
What is the role of PARL in metallopeptidase regulation?
PARL is a mitochondrial metallopeptidase regulated by autocatalytic cleavage, and it controls apoptosis and calcium homeostasis.
How does PAPP-A regulate metallopeptidase activity?
PAPP-A is a metallopeptidase that cleaves IGFBP-4, thereby increasing IGF bioavailability and promoting cell growth.
What experimental models are used to study metallopeptidase regulation?
Knockout, point mutation, knock-in, and overexpression models in cell lines and mice are commonly used.
Can CRISPR be used to study metallopeptidase regulation?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools to dissect regulatory mechanisms.
What are TIMPs?
TIMPs are tissue inhibitors of metalloproteinases that bind and inhibit MMP activity, playing key roles in cancer and tissue remodeling.
How does ulilysin latency work?
Ulilysin is a metallopeptidase with a latency mechanism that can be relieved by structural changes, and it is inhibited by sulfonyl-fluoride compounds.
Conclusion
Regulation of metallopeptidase activity (GO:1905048) is a fundamental biological process that controls proteolysis in health and disease. From autoinhibition of bacterial BepA to the complex regulation of human MMPs and PAPP-A, diverse mechanisms ensure that metallopeptidases act only when and where needed. Dysregulation contributes to cancer, neurodegeneration, and metabolic disorders, making these regulatory pathways attractive therapeutic targets. Advances in CRISPR-based models and high-throughput screening are accelerating our understanding of this process. EDITGENE stands ready to support researchers with tailored CRISPR services to explore the regulation of metallopeptidase activity in any biological context.
References
- 1. D'Angelo D et al.. 2025. Impact of PARL-mediated mitochondrial protease activity on calcium regulation.. Biochim Biophys Acta Mol Cell Res 1872(7):119998 PMID: 40484322
- 2. Daimon Y et al.. 2020. Reversible autoinhibitory regulation of Escherichia coli metallopeptidase BepA for selective β-barrel protein degradation.. Proc Natl Acad Sci U S A 117(45):27989-27996 PMID: 33093205
- 3. Ascher DB et al.. 2011. Regulation of insulin-regulated membrane aminopeptidase activity by its C-terminal domain.. Biochemistry 50(13):2611-22 PMID: 21348480
- 4. Jeyaraju DV et al.. 2011. Structural and mechanistic basis of Parl activity and regulation.. Cell Death Differ 18(9):1531-9 PMID: 21415861
- 5. Rodríguez-Banqueri A et al.. 2023. Structural insights into latency of the metallopeptidase ulilysin (lysargiNase) and its unexpected inhibition by a sulfonyl-fluoride inhibitor of serine peptidases.. Dalton Trans 52(12):3610-3622 PMID: 36857690
- 6. Conover CA et al.. 2023. The Pregnancy-Associated Plasma Protein-A (PAPP-A) Story.. Endocr Rev 44(6):1012-1028 PMID: 37267421
- 7. Yan C et al.. 2007. Regulation of matrix metalloproteinase gene expression.. J Cell Physiol 211(1):19-26 PMID: 17167774
- 8. Frieling JS et al.. 2019. Proteolytic Regulation of Parathyroid Hormone-Related Protein: Functional Implications for Skeletal Malignancy.. Int J Mol Sci 20(11) PMID: 31181800
